Yes I will go back to that article. The company's claims of all of Kevetrin's MoA from pre-clinicals are exciting. If they prove out in clinicals, WOW. But I have to see it to believe it (the initial data from the Phase 1 are encouraging). This is science, not theology. I suspect the market feel the same way.